Paper Details
- Home
- Paper Details
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Author: AjjanRamzi A, AngiolilloDominick J, BassTheodore A, BhattiMona, ChoJung Rae, DeGroatChristopher, FranchiFrancesco, GuzmanLuis A, KingRhodri, PhoenixFladia, RolliniFabiana, Tello-MontoliuAntonio, ZenniMartin M
Original Abstract of the Article :
There is growing interest in understanding the effects of adding an oral anticoagulant in patients on dual antiplatelet therapy (DAPT). Vitamin K antagonists (VKAs) and clopidogrel represent the most broadly utilised oral anticoagulant and P2Y12 receptor inhibitor, respectively. However, VKAs can in...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1160/TH15-06-0467
データ提供:米国国立医学図書館(NLM)
Dabigatran's Effects on Coagulation in Patients on Dual Antiplatelet Therapy
Coronary artery disease (CAD) is a major health concern, and its management often involves dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. This study investigates the effects of adding dabigatran, a direct-acting oral anticoagulant, to DAPT in patients with CAD. It's like navigating the delicate balance of a desert ecosystem, where different medications work together to achieve the desired therapeutic effect.
The researchers found that dabigatran, while significantly interfering with thrombin activity and delaying fibrin clot formation, did not modulate platelet reactivity. This suggests that dabigatran could be a safe and effective addition to DAPT in certain patients with CAD, offering enhanced anticoagulation without compromising platelet function. However, further research is needed to explore the optimal use of dabigatran in this context.
Dabigatran's Role in Coronary Artery Disease Management
This study sheds light on the potential benefits of dabigatran as an adjunct to DAPT in patients with CAD. The findings suggest that dabigatran could offer enhanced anticoagulation without negatively affecting platelet function, potentially improving patient outcomes. This research adds valuable insights to the ongoing debate about the optimal management of CAD.
Implications for Cardiovascular Health and Treatment
This research contributes to our understanding of the complex interplay between different medications in managing cardiovascular disease. It suggests that dabigatran, when used judiciously, could be a valuable tool in optimizing treatment for patients with CAD. This research could lead to the development of more personalized and effective treatment strategies for CAD patients.
Dr.Camel's Conclusion
This research is like a map guiding us through the complex terrain of cardiovascular medications. It reveals the potential of dabigatran to enhance anticoagulation in patients on DAPT without compromising platelet function, a delicate balance akin to navigating a desert oasis. It's a reminder that understanding the interplay of different medications is crucial for achieving optimal outcomes in treating complex health conditions.
Date :
- Date Completed 2017-02-10
- Date Revised 2022-01-29
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.